Citadel Advisors’s BioCardia BCDA Stock Holding History

Citadel Advisors’s Portfolio BCDA Stock Details BCDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-67	Closed	-$664	–	14554
2023 Q4	$664	Sell	67 -246	-79%	-$2K	﹤0.01%	13972
2023 Q3	$2.01K	Sell	313 -780	-71%	-$13.1K	﹤0.01%	13773
2023 Q2	$43.8K	Sell	1,093 -2,287	-68%	-$70.5K	﹤0.01%	11964
2023 Q1	$99.4K	Buy	3,380 +1,573	+87%	+$52.2K	﹤0.01%	11270
2022 Q4	$56.6K	Buy	1,807 +114	+7%	+$3.24K	﹤0.01%	11971
2022 Q3	$49K	Buy	+1,693	New	+$43.8K	﹤0.01%	11642
2022 Q2	–	Sell	-2,573	Closed	-$80K	–	12870
2022 Q1	$80K	Sell	2,573 -67	-3%	-$1.99K	﹤0.01%	12477
2021 Q4	$77K	Buy	+2,640	New	+$96.8K	﹤0.01%	12970
2021 Q2	–	Sell	-2,360	Closed	-$154K	–	13659
2021 Q1	$154K	Buy	+2,360	New	+$147K	﹤0.01%	11995

Other funds holding BCDA

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pingora Partners Wilson, Wyoming $169M AUM 56.08% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Citadel Advisors's BCDA Position: Q1 2026 in Review

Citadel Advisors reduced its BioCardia (BCDA) stake by 33% in Q1 2026, selling an estimated $38.6K and leaving 63,384 shares worth $76.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12204.

Citadel Advisors first reported a position in BCDA in Q4 2020 and has held it in 13 quarters since. The position peaked at $125K in Q2 2021. 18 funds tracked by Wall St. Rank hold BCDA as of Q1 2026.

Citadel Advisors held 63,384 shares of BioCardia worth $76.7K as of Q1 2026.
Citadel Advisors sold 30,863 BioCardia shares in Q1 2026, an estimated $38.6K.
BioCardia made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12204 holding.
Citadel Advisors first reported a position in BioCardia in Q4 2020 and has held it in 13 quarters since.
Citadel Advisors's BioCardia position peaked at $125K in Q2 2021.
18 funds tracked by Wall St. Rank held BioCardia as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.